Northwestern Mutual Wealth Management’s BridgeBio Oncology BBOT Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.3K	Buy	+1,350	New	+$11.3K	﹤0.01%	3109

Other funds holding BBOT

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northwestern Mutual Wealth Management's BBOT Position: Q2 2026 in Review

Northwestern Mutual Wealth Management opened a new position in BridgeBio Oncology (BBOT) in Q2 2026: 1,350 shares worth $10.3K. The stake represents ﹤0.01% of the portfolio and ranks #3109 among its holdings.

66 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

Northwestern Mutual Wealth Management held 1,350 shares of BridgeBio Oncology worth $10.3K as of Q2 2026.
BridgeBio Oncology was a new Northwestern Mutual Wealth Management position in Q2 2026.
BridgeBio Oncology made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q2 2026, its #3109 holding.
66 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.